PriceTargets.com logo

Inspire Medical Systems - INSP Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $302.63
  • Forecasted Upside: 29.29%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$234.07 As of 03/31/2023 01:00 AM ET
▼ -3.93 (-1.65%)

This chart shows the closing price for INSP by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Inspire Medical Systems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INSP and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INSP

Analyst Price Target is $302.63
▲ +29.29% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Inspire Medical Systems in the last 3 months. The average price target is $302.63, with a high forecast of $330.00 and a low forecast of $270.00. The average price target represents a 29.29% upside from the last price of $234.07.

This chart shows the closing price for INSP for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 7 investment analysts is to buy stock in Inspire Medical Systems. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/6/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/6/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
7/5/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
10/3/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
1/1/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/2/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
4/1/2023

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/28/2023UBS GroupInitiated CoverageBuy$300.00Low
2/8/2023Lake Street CapitalBoost Target$250.00 ➝ $305.00Low
2/8/2023JPMorgan Chase & Co.Boost TargetOverweight$271.00 ➝ $300.00Low
2/8/2023Truist FinancialBoost TargetBuy$310.00 ➝ $330.00Low
2/8/2023Piper SandlerBoost TargetOverweight$300.00 ➝ $305.00Low
1/31/2023Truist FinancialBoost TargetBuy$308.00 ➝ $310.00Low
1/26/2023Piper SandlerBoost TargetOverweight$285.00 ➝ $300.00Low
1/13/2023KeyCorpBoost TargetOverweight$287.00 ➝ $303.00Low
12/20/2022Truist FinancialBoost TargetBuy$270.00 ➝ $308.00Low
12/13/2022The Goldman Sachs GroupUpgradeNeutral ➝ Buy$245.00 ➝ $308.00Low
12/13/2022KeyCorpInitiated CoverageOverweight$287.00Low
11/2/2022Lake Street CapitalLower Target$320.00 ➝ $250.00Low
10/17/2022Truist FinancialLower TargetBuy$280.00 ➝ $240.00Low
8/3/2022Piper SandlerLower TargetOverweight$310.00 ➝ $285.00Low
6/10/2022Truist FinancialLower TargetBuy$296.00 ➝ $250.00Medium
5/4/2022Piper SandlerBoost Target$305.00 ➝ $310.00High
4/12/2022Truist FinancialInitiated CoverageBuy$315.00High
4/5/2022Wolfe ResearchInitiated CoverageMarket Perform$270.00Medium
3/2/2022Bank of AmericaInitiated CoverageBuy ➝ BuyHigh
2/9/2022SVB LeerinkBoost TargetOutperform$270.00 ➝ $273.00High
11/3/2021Lake Street CapitalBoost TargetBuy$260.00 ➝ $320.00Medium
11/3/2021Wells Fargo & CompanyBoost TargetOverweight$250.00 ➝ $305.00Medium
11/3/2021SVB LeerinkBoost TargetOutperform$300.00 ➝ $325.00Medium
11/3/2021Piper SandlerBoost TargetPositive ➝ Overweight$238.00 ➝ $305.00Medium
10/22/2021SVB LeerinkReiterated RatingOutperformHigh
9/24/2021SVB LeerinkBoost TargetOutperform$265.00 ➝ $300.00Low
8/4/2021SVB LeerinkLower TargetOutperform$275.00 ➝ $265.00High
8/4/2021Piper SandlerBoost TargetOverweight$215.00 ➝ $238.00High
7/20/2021Piper SandlerLower TargetOverweight$235.00 ➝ $215.00High
7/14/2021Piper SandlerLower TargetOverweight ➝ Overweight$255.00 ➝ $235.00High
6/23/2021SVB LeerinkReiterated RatingBuyMedium
5/25/2021SVB LeerinkReiterated RatingBuyMedium
5/5/2021Lake Street CapitalBoost TargetBuy$250.00 ➝ $260.00High
5/5/2021Piper SandlerBoost TargetPositive ➝ Overweight$252.00 ➝ $255.00High
4/25/2021Robert W. BairdReiterated RatingBuyHigh
2/24/2021Piper SandlerBoost TargetOverweight$210.00 ➝ $252.00Medium
2/24/2021Lake Street CapitalBoost TargetBuy$215.00 ➝ $250.00Low
2/24/2021SVB LeerinkBoost TargetOutperform$225.00 ➝ $275.00High
1/7/2021Lake Street CapitalBoost TargetBuy$150.00 ➝ $215.00Low
1/4/2021Bank of AmericaDowngradeBuy ➝ NeutralN/A
12/15/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$162.00 ➝ $209.00Low
12/3/2020Piper SandlerBoost TargetOverweight$147.00 ➝ $210.00Medium
11/3/2020Wells Fargo & CompanyBoost TargetOverweight$135.00 ➝ $140.00High
11/3/2020SVB LeerinkBoost TargetOutperform$150.00 ➝ $170.00High
11/3/2020Robert W. BairdBoost TargetOutperform$130.00 ➝ $160.00High
11/3/2020Bank of AmericaUpgradeNeutral ➝ Buy$125.00 ➝ $155.00High
11/3/2020Piper SandlerBoost TargetOverweight$137.00 ➝ $147.00High
11/3/2020OppenheimerUpgradeUnderperform ➝ Market PerformHigh
9/22/2020JPMorgan Chase & Co.Initiated CoverageOverweight$148.00High
9/18/2020Piper SandlerBoost TargetPositive ➝ Overweight$116.00 ➝ $137.00High
9/10/2020Wells Fargo & CompanyBoost TargetOverweight$125.00 ➝ $135.00Medium
9/9/2020SVB LeerinkBoost TargetPositive ➝ Outperform$120.00 ➝ $150.00High
9/1/2020Robert W. BairdInitiated CoverageOutperform$130.00Low
8/21/2020Stifel NicolausBoost Target$110.00 ➝ $125.00Low
8/6/2020Wells Fargo & CompanyBoost TargetPositive ➝ Overweight$115.00 ➝ $125.00Medium
8/6/2020Bank of AmericaDowngradeBuy ➝ Neutral$115.00High
8/5/2020Piper SandlerBoost Target$98.00 ➝ $111.00Low
8/5/2020SVB LeerinkBoost TargetOutperform$110.00 ➝ $120.00High
8/5/2020Lake Street CapitalBoost TargetBuy$100.00 ➝ $130.00High
8/5/2020OppenheimerReiterated RatingSell$42.00 ➝ $50.00High
7/15/2020The Goldman Sachs GroupInitiated CoverageBuy$148.00High
6/29/2020SVB LeerinkBoost TargetOutperform$85.00 ➝ $110.00Low
6/18/2020Piper SandlerBoost TargetOverweight$81.00 ➝ $98.00Medium
5/26/2020Wells Fargo & CompanyBoost TargetOverweight$81.00 ➝ $95.00High
5/18/2020Lake Street CapitalInitiated CoverageBuy$90.00High
5/6/2020GuggenheimBoost TargetBuy$80.00 ➝ $90.00High
5/6/2020OppenheimerInitiated CoverageSell$42.00High
4/28/2020Bank of AmericaUpgradeNeutral ➝ Buy$90.00High
4/19/2020Piper SandlerInitiated CoverageOverweight$74.00Medium
4/15/2020Stifel NicolausBoost TargetBuy$88.00 ➝ $95.00Low
4/9/2020Piper SandlerInitiated CoverageOverweight$74.00High
4/2/2020OppenheimerLower Target$50.00 ➝ $42.00Medium
2/26/2020Bank of AmericaBoost TargetNeutral$75.00 ➝ $85.00High
2/26/2020Stifel NicolausBoost TargetBuy$82.00 ➝ $88.00High
2/26/2020SVB LeerinkBoost TargetOutperform$75.00 ➝ $97.00High
2/26/2020Wells Fargo & CompanyBoost TargetOverweight$90.00 ➝ $93.00High
1/27/2020OppenheimerInitiated CoverageUnderperform$50.00High
1/16/2020Wells Fargo & CompanyBoost TargetOverweight$70.00 ➝ $90.00High
11/6/2019Berenberg BankUpgradeSell ➝ Hold$46.00 ➝ $51.00High
9/27/2019Dougherty & CoSet TargetBuy$78.00High
7/8/2019Bank of AmericaReiterated RatingPositive ➝ Neutral$65.00 ➝ $75.00Low
2/5/2019Dougherty & CoInitiated CoverageBuy ➝ Buy$64.00High
11/28/2018Berenberg BankInitiated CoverageSell ➝ Sell$31.00High
10/29/2018SVB LeerinkInitiated CoverageOutperform ➝ Outperform$57.00High
5/29/2018Wells Fargo & CompanyInitiated CoverageOutperform$38.00High
5/29/2018Bank of AmericaInitiated CoverageNeutral$36.00High
5/29/2018GuggenheimInitiated CoverageBuy$40.00High
5/29/2018The Goldman Sachs GroupInitiated CoverageNeutral$25.00High
5/29/2018Stifel NicolausInitiated CoverageBuy$42.00High
(Data available from 4/1/2018 forward)

News Sentiment Rating

1.33 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 4 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/3/2022
  • 6 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/3/2022
  • 9 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/2/2022
  • 9 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/2/2022
  • 9 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
1/1/2023
  • 16 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/31/2023
  • 20 very positive mentions
  • 10 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
3/2/2023
  • 17 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/1/2023

Current Sentiment

  • 17 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Inspire Medical Systems logo
Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.
Read More

Today's Range

Now: $234.07
Low: $232.84
High: $242.76

50 Day Range

MA: $254.04
Low: $229.06
High: $278.01

52 Week Range

Now: $234.07
Low: $142.74
High: $282.31

Volume

464,791 shs

Average Volume

334,424 shs

Market Capitalization

$6.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.47

Frequently Asked Questions

What sell-side analysts currently cover shares of Inspire Medical Systems?

The following Wall Street sell-side analysts have issued research reports on Inspire Medical Systems in the last twelve months: JPMorgan Chase & Co., KeyCorp, Lake Street Capital, Piper Sandler, The Goldman Sachs Group, Inc., TheStreet, Truist Financial Co., UBS Group AG, and Wolfe Research.
View the latest analyst ratings for INSP.

What is the current price target for Inspire Medical Systems?

8 Wall Street analysts have set twelve-month price targets for Inspire Medical Systems in the last year. Their average twelve-month price target is $302.63, suggesting a possible upside of 29.3%. Truist Financial Co. has the highest price target set, predicting INSP will reach $330.00 in the next twelve months. Wolfe Research has the lowest price target set, forecasting a price of $270.00 for Inspire Medical Systems in the next year.
View the latest price targets for INSP.

What is the current consensus analyst rating for Inspire Medical Systems?

Inspire Medical Systems currently has 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INSP will outperform the market and that investors should add to their positions of Inspire Medical Systems.
View the latest ratings for INSP.

What other companies compete with Inspire Medical Systems?

Other companies that are similar to Inspire Medical Systems include Stevanato Group, Shockwave Medical, NovoCure, Globus Medical and Integra LifeSciences. Learn More about companies similar to Inspire Medical Systems.

How do I contact Inspire Medical Systems' investor relations team?

Inspire Medical Systems' physical mailing address is 5500 WAYZATA BLVD SUITE 1600, GOLDEN VALLEY MN, 55416. The company's listed phone number is (844) 672-4357 and its investor relations email address is [email protected] The official website for Inspire Medical Systems is www.inspiresleep.com. Learn More about contacing Inspire Medical Systems investor relations.